Develops drugs for rare endocrine diseases.
Dec 2025Revenue €720M/yrExpenses €856M/yr
Expected break-even Jun 2026
Figures by year
When will Ascendis Pharma A/S be profitable?
Its revenue and expense trends are projected to cross in Jun 2026. In the 12 months to Dec 2025, revenue was €720M and expenses €856M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | €720M | €856M | −€136M |
| Dec 2024 | €364M | €642M | −€279M |
| Dec 2023 | €267M | €722M | −€456M |
| Dec 2022 | €51.2M | €613M | −€562M |
| Dec 2021 | €7.78M | €460M | −€452M |
| Dec 2020 | €6.95M | €338M | −€331M |
| Dec 2019 | €13.4M | €240M | −€227M |
| Dec 2018 | €10.6M | €165M | −€155M |
| Dec 2017 | €1.53M | €113M | −€112M |
| Dec 2016 | €4.61M | €77.5M | −€72.9M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.